Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Phase 3Active, not recruiting
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Sep 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of sotagliflozin in hypertrophic cardiomyopathy (HCM), sponsored by Lexicon Pharmaceuticals, Inc.. Started Sep 2024; status: active, not recruiting.
02
Drugs
sotagliflozin
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06481891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481891.